Cargando…
Nobiletin-loaded micelles reduce ovariectomy-induced bone loss by suppressing osteoclastogenesis
BACKGROUND: Nobiletin (NOB), a polymethoxy flavonoid, possesses anti-cancer and anti-inflammatory activities, has been reported that it played role in anti-osteoporosis treatment. However, previous research did not focus on practical use due to lack of hydrophilicity and cytotoxicity at high concent...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769031/ https://www.ncbi.nlm.nih.gov/pubmed/31576127 http://dx.doi.org/10.2147/IJN.S213724 |
_version_ | 1783455168672563200 |
---|---|
author | Wang, Yabing Xie, Jian Ai, Zexin Su, Jiansheng |
author_facet | Wang, Yabing Xie, Jian Ai, Zexin Su, Jiansheng |
author_sort | Wang, Yabing |
collection | PubMed |
description | BACKGROUND: Nobiletin (NOB), a polymethoxy flavonoid, possesses anti-cancer and anti-inflammatory activities, has been reported that it played role in anti-osteoporosis treatment. However, previous research did not focus on practical use due to lack of hydrophilicity and cytotoxicity at high concentrations. The aim of this study was to develop a therapeutic formulation for osteoporosis based on the utilization of NOB. METHODS: In this study, NOB-loaded poly(ethylene glycol)-block-poly(e-caprolactone) (NOB-PEG-PCL) was prepared by dialysis method. The effects on osteoclasts and anti-osteoporosis functions were investigated in a RANKL-induced cell model and ovariectomized (OVX) mice. RESULTS: Dynamic light scattering and transmission electron microscopy examination results revealed that the NOB-PEG-PCL had a round shape, with a mean diameter around 124 nm. The encapsulation efficiency and drug loading were 76.34±3.25% and 7.60±0.48%, respectively. The in vitro release of NOB from NOB-PEG-PCL showed a remarkably sustained releasing characteristic and could be retained at least 48 hrs in pH 7.4 PBS. Anti-osteoclasts effects demonstrated that the NOB-PEG-PCL significantly inhibited the formation of tartrate-resistant acid phosphatase (TRAP)-positive multinuclear cells stimulated by RANKL. Furthermore, the NOB-PEG-PCL did not produce cytotoxicity on bone marrow-derived macrophages (BMMs). The mRNA expressions of genetic markers of osteoclasts including TRAP and cathepsin K were significantly decreased in the presence of NOB-PEG-PCL. In addition, the NOB-PEG-PCL inhibited OC differentiation of BMMs through RANKL-induced MAPK signal pathway. After administration of the NOB-PEG-PCL, NOB-PEG-PCL prevented bone loss and improved bone density in OVX mice. These findings suggest that NOB-PEG-PCL might have great potential in the treatment of osteoporosis. CONCLUSION: The results suggested that NOB-PEG-PCL micelles could effectively prevent NOB fast release from micelles and extend circulation time. The NOB-PEG-PCL delivery system may be a promising way to prevent and treat osteoporosis. |
format | Online Article Text |
id | pubmed-6769031 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-67690312019-10-01 Nobiletin-loaded micelles reduce ovariectomy-induced bone loss by suppressing osteoclastogenesis Wang, Yabing Xie, Jian Ai, Zexin Su, Jiansheng Int J Nanomedicine Original Research BACKGROUND: Nobiletin (NOB), a polymethoxy flavonoid, possesses anti-cancer and anti-inflammatory activities, has been reported that it played role in anti-osteoporosis treatment. However, previous research did not focus on practical use due to lack of hydrophilicity and cytotoxicity at high concentrations. The aim of this study was to develop a therapeutic formulation for osteoporosis based on the utilization of NOB. METHODS: In this study, NOB-loaded poly(ethylene glycol)-block-poly(e-caprolactone) (NOB-PEG-PCL) was prepared by dialysis method. The effects on osteoclasts and anti-osteoporosis functions were investigated in a RANKL-induced cell model and ovariectomized (OVX) mice. RESULTS: Dynamic light scattering and transmission electron microscopy examination results revealed that the NOB-PEG-PCL had a round shape, with a mean diameter around 124 nm. The encapsulation efficiency and drug loading were 76.34±3.25% and 7.60±0.48%, respectively. The in vitro release of NOB from NOB-PEG-PCL showed a remarkably sustained releasing characteristic and could be retained at least 48 hrs in pH 7.4 PBS. Anti-osteoclasts effects demonstrated that the NOB-PEG-PCL significantly inhibited the formation of tartrate-resistant acid phosphatase (TRAP)-positive multinuclear cells stimulated by RANKL. Furthermore, the NOB-PEG-PCL did not produce cytotoxicity on bone marrow-derived macrophages (BMMs). The mRNA expressions of genetic markers of osteoclasts including TRAP and cathepsin K were significantly decreased in the presence of NOB-PEG-PCL. In addition, the NOB-PEG-PCL inhibited OC differentiation of BMMs through RANKL-induced MAPK signal pathway. After administration of the NOB-PEG-PCL, NOB-PEG-PCL prevented bone loss and improved bone density in OVX mice. These findings suggest that NOB-PEG-PCL might have great potential in the treatment of osteoporosis. CONCLUSION: The results suggested that NOB-PEG-PCL micelles could effectively prevent NOB fast release from micelles and extend circulation time. The NOB-PEG-PCL delivery system may be a promising way to prevent and treat osteoporosis. Dove 2019-09-26 /pmc/articles/PMC6769031/ /pubmed/31576127 http://dx.doi.org/10.2147/IJN.S213724 Text en © 2019 Wang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Wang, Yabing Xie, Jian Ai, Zexin Su, Jiansheng Nobiletin-loaded micelles reduce ovariectomy-induced bone loss by suppressing osteoclastogenesis |
title | Nobiletin-loaded micelles reduce ovariectomy-induced bone loss by suppressing osteoclastogenesis |
title_full | Nobiletin-loaded micelles reduce ovariectomy-induced bone loss by suppressing osteoclastogenesis |
title_fullStr | Nobiletin-loaded micelles reduce ovariectomy-induced bone loss by suppressing osteoclastogenesis |
title_full_unstemmed | Nobiletin-loaded micelles reduce ovariectomy-induced bone loss by suppressing osteoclastogenesis |
title_short | Nobiletin-loaded micelles reduce ovariectomy-induced bone loss by suppressing osteoclastogenesis |
title_sort | nobiletin-loaded micelles reduce ovariectomy-induced bone loss by suppressing osteoclastogenesis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769031/ https://www.ncbi.nlm.nih.gov/pubmed/31576127 http://dx.doi.org/10.2147/IJN.S213724 |
work_keys_str_mv | AT wangyabing nobiletinloadedmicellesreduceovariectomyinducedbonelossbysuppressingosteoclastogenesis AT xiejian nobiletinloadedmicellesreduceovariectomyinducedbonelossbysuppressingosteoclastogenesis AT aizexin nobiletinloadedmicellesreduceovariectomyinducedbonelossbysuppressingosteoclastogenesis AT sujiansheng nobiletinloadedmicellesreduceovariectomyinducedbonelossbysuppressingosteoclastogenesis |